Alignment Healthcare (NASDAQ:ALHC) Releases Quarterly Earnings Results, Beats Estimates By $0.04 EPS

Alignment Healthcare (NASDAQ:ALHC) posted its quarterly earnings results on Thursday. The company reported $0.17 earnings per share for the quarter, topping analysts’ consensus estimates of $0.13 by $0.04, FiscalAI reports. Alignment Healthcare had a net margin of 0.89% and a return on equity of 22.28%. The firm had revenue of $1.34 billion for the quarter, compared to analyst estimates of $1.31 billion. During the same period in the previous year, the business posted $0.07 earnings per share. Alignment Healthcare’s quarterly revenue was up 31.6% on a year-over-year basis.

Here are the key takeaways from Alignment Healthcare’s conference call:

• Strong second-quarter results: Membership rose 31% year over year to 294,100, revenue increased 32% to $1.3 billion, and adjusted EBITDA grew 48% to $68 million, with a 60-basis-point margin expansion.
• Alignment raised its 2026 membership and revenue outlook, increased the low end of its adjusted gross profit guidance by $10 million and adjusted EBITDA guidance by $7 million, and remains on track for its full-year targets.
• Management estimates approximately $880 million of embedded adjusted gross profit potential in its current membership base, as roughly half of members remain in their first or second year and are expected to become more profitable as clinical programs mature.
• The latest AVA AI stratification model can identify the 10% of members expected to account for nearly 70% of hospital admissions over the following 30 days, supporting more targeted intervention by Care Anywhere teams.
• Third-quarter profitability is expected to be seasonally weaker, with only about 30% of full-year adjusted EBITDA projected in the second half; higher-acuity new members, Part D trends, and additional clinical, AI, automation, hiring, and market-preparation investments are expected to pressure MBR and SG&A.

Alignment Healthcare Trading Down 20.2%

NASDAQ:ALHC opened at $14.85 on Friday. The firm has a market cap of $3.07 billion, a PE ratio of 78.16, a price-to-earnings-growth ratio of 2.51 and a beta of 1.05. The stock has a fifty day moving average price of $19.70 and a 200 day moving average price of $19.76. Alignment Healthcare has a 12-month low of $12.91 and a 12-month high of $25.12. The company has a current ratio of 1.58, a quick ratio of 1.58 and a debt-to-equity ratio of 1.56.

Alignment Healthcare News Summary

Here are the key news stories impacting Alignment Healthcare this week:

• Positive Sentiment: Q2 results exceeded expectations: Alignment reported adjusted earnings of $0.17 per share, above the $0.13 consensus estimate, while revenue of $1.34 billion surpassed estimates of $1.31 billion. Revenue increased 31.6% year over year, and net income more than doubled to $36.6 million as Medicare Advantage care costs improved. Alignment Healthcare Reports Second Quarter 2026 Results
• Positive Sentiment: Operating performance is improving: The company said it surpassed the high end of its guidance across key metrics, reflecting stronger membership growth, revenue, and profitability compared with the prior-year period. Alignment Healthcare Turns Profit
• Neutral Sentiment: Guidance remained broadly in line: Full-year 2026 revenue guidance was approximately $5.2 billion, and third-quarter revenue guidance was approximately $1.3 billion, generally matching analyst expectations. The lack of a material forecast increase may have limited the earnings-driven upside.
• Negative Sentiment: Several law firms announced investigations: Frank R. Cruz, Block & Leviton, Kaplan Fox, Lowey Dannenberg, and Pomerantz publicized inquiries into possible securities-law violations and alleged financial manipulation. The investigations follow an earlier sharp drop in ALHC shares and could create legal costs, reputational damage, and uncertainty regarding the company’s disclosures. The allegations have not been proven. Securities Fraud Investigation Into Alignment Healthcare

Insider Activity

In related news, insider Mark D. Kent acquired 14,848 shares of the firm’s stock in a transaction dated Tuesday, June 2nd. The stock was acquired at an average price of $13.31 per share, for a total transaction of $197,626.88. Following the purchase, the insider owned 14,848 shares of the company’s stock, valued at $197,626.88. This represents a ? increase in their position. The transaction was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO John E. Kao sold 298,000 shares of the business’s stock in a transaction dated Wednesday, June 10th. The stock was sold at an average price of $20.36, for a total value of $6,067,280.00. Following the transaction, the chief executive officer directly owned 1,386,766 shares of the company’s stock, valued at approximately $28,234,555.76. This represents a 17.69% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders sold a total of 1,039,951 shares of company stock worth $19,976,967 over the last three months. Company insiders own 5.20% of the company’s stock.

Institutional Trading of Alignment Healthcare

Hedge funds have recently added to or reduced their stakes in the company. Royal Bank of Canada lifted its stake in Alignment Healthcare by 92.6% in the first quarter. Royal Bank of Canada now owns 92,379 shares of the company’s stock worth $1,720,000 after acquiring an additional 44,413 shares during the last quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. raised its holdings in shares of Alignment Healthcare by 4.6% in the 1st quarter. MIRAE ASSET GLOBAL ETFS HOLDINGS Ltd. now owns 59,557 shares of the company’s stock valued at $1,109,000 after purchasing an additional 2,594 shares in the last quarter. Goldman Sachs Group Inc. raised its holdings in shares of Alignment Healthcare by 79.1% in the 1st quarter. Goldman Sachs Group Inc. now owns 972,715 shares of the company’s stock valued at $18,112,000 after purchasing an additional 429,703 shares in the last quarter. Woodline Partners LP purchased a new stake in shares of Alignment Healthcare during the 1st quarter worth $2,142,000. Finally, UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC lifted its position in shares of Alignment Healthcare by 16.9% during the 1st quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 307,655 shares of the company’s stock worth $5,729,000 after purchasing an additional 44,452 shares during the last quarter. Institutional investors and hedge funds own 86.19% of the company’s stock.

Analyst Upgrades and Downgrades

A number of equities analysts have weighed in on ALHC shares. UBS Group reissued a “neutral” rating on shares of Alignment Healthcare in a research note on Wednesday, July 8th. Wolfe Research began coverage on shares of Alignment Healthcare in a research report on Friday, April 17th. They set an “outperform” rating and a $24.00 price target on the stock. Raymond James Financial set a $22.00 target price on Alignment Healthcare in a research report on Thursday, May 7th. KeyCorp reaffirmed an “overweight” rating on shares of Alignment Healthcare in a research report on Wednesday, June 10th. Finally, Zacks Research downgraded shares of Alignment Healthcare from a “strong-buy” rating to a “hold” rating in a report on Monday, July 6th. Six research analysts have rated the stock with a Buy rating and four have given a Hold rating to the company’s stock. Based on data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus target price of $24.30.

Alignment Healthcare Company Profile

Alignment Healthcare, Inc (NASDAQ: ALHC) is a health care company specializing in value-based care for Medicare Advantage beneficiaries. The company leverages an integrated care model that combines in-home clinical services, telehealth capabilities and digital health tools to manage chronic conditions, improve outcomes and enhance patient experience.

At the core of Alignment Healthcare’s approach is a proprietary technology platform that aggregates real-time clinical and claims data to support preventive care, risk stratification and personalized care plans.